<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013

    PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

    Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    May 14, 2014

    Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)

    Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013

    Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

    Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    November 2, 2011

    Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

    Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)

    November 6, 2015

    Biodesix data on proteomic and genomic blood-based assays presented at EORTC

    Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

    January 30, 2012

    Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.

    Biodesix Secures Medicare Coverage for VeriStrat Test

    June 20, 2013

    Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

    Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    March 3, 2014

    CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.

    Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    February 27, 2012

    Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).

    Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

    October 27, 2014

    VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).
    1 2